Arcutis Biotherapeutics Inc.

27.81+0.7100+2.62%Vol 67.18K1Y Perf -11.77%
Apr 13th, 2021 16:00 DELAYED
BID27.72 ASK27.80
Open27.25 Previous Close27.10
Pre-Market- After-Market-
 - -  - -%
Target Price
59.33 
Analyst Rating
Strong Buy 1.00
Potential %
113.34 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.39B 
Earnings Rating
Price Range Ratio 52W %
46.11 
Earnings Date
11th May 2021

Today's Price Range

26.8828.05

52W Range

17.5139.85

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-0.64%
1 Month
-14.56%
3 Months
-2.39%
6 Months
15.01%
1 Year
-11.77%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARQT27.810.71002.62
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.89-0.7911.24
Q03 2020-0.95-1.01-6.32
Q02 2020--0.94-
Q01 2020--1.15-
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume67.18K
Shares Outstanding50.09M
Trades Count996
Dollar Volume6.52M
Avg. Volume247.32K
Avg. Weekly Volume130.28K
Avg. Monthly Volume185.85K
Avg. Quarterly Volume269.53K

Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) stock closed at 27.81 per share at the end of the most recent trading day (a 2.62% change compared to the prior day closing price) with a volume of 67.18K shares and market capitalization of 1.39B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 54 people. Arcutis Biotherapeutics Inc. CEO is Todd Franklin Watanabe.

The one-year performance of Arcutis Biotherapeutics Inc. stock is -11.77%, while year-to-date (YTD) performance is -1.14%. ARQT stock has a five-year performance of %. Its 52-week range is between 17.51 and 39.85, which gives ARQT stock a 52-week price range ratio of 46.11%

Arcutis Biotherapeutics Inc. currently has a PE ratio of -7.20, a price-to-book (PB) ratio of 5.10, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -66.96%, a ROC of -183.93% and a ROE of -131.99%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Arcutis Biotherapeutics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Arcutis Biotherapeutics Inc.’s next earnings report date is 11th May 2021.

The consensus rating of Wall Street analysts for Arcutis Biotherapeutics Inc. is Strong Buy (1), with a target price of $59.33, which is +113.34% compared to the current price. The earnings rating for Arcutis Biotherapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Arcutis Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Arcutis Biotherapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.13, ATR14 : 2.36, CCI20 : -63.67, Chaikin Money Flow : -0.06, MACD : -0.75, Money Flow Index : 32.08, ROC : -1.35, RSI : 54.36, STOCH (14,3) : 38.57, STOCH RSI : 1.00, UO : 40.05, Williams %R : -61.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Arcutis Biotherapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The firm's lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.

CEO: Todd Franklin Watanabe

Telephone: +1 805 418-5006

Address: 2945 Townsgate Road, Westlake Village 91361, CA, US

Number of employees: 54

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

60%40%

Bearish Bullish

63%37%

News

Stocktwits